<p>根据 Blair William &amp; Co. IL 在最近向证券交易委员会提交的 13F 文件，该公司在第二季度购买了 Solid Biosciences Inc.（NASDAQ:SLDB - 免费报告）股票的新头寸。该公司购买了 165,700 股，价值约为 807,000 美元。Blair William &amp; Co. IL 在最近一个季度末持有 Solid Biosciences 约 0.21% 的股份。</p>
<p>获取 <strong>Solid Biosciences</strong> 警报：</p>
<ul>
<li>Sarepta 在 2025 年遭遇重创——分析师仍然预测 179% 的上涨空间</li>
</ul>
<p>其他一些对冲基金和机构投资者最近也增加或减少了在 SLDB 的持股。Adage Capital Partners GP L.L.C.在第一季度将其在 Solid Biosciences 的持股增加了 285.0%。Adage Capital Partners GP L.L.C.现在持有 6,729,484 股该公司的股票，价值 2498.9 万美元，此前在上个季度又购买了 4,981,400 股。Bain Capital Life Sciences Investors LLC 在第一季度将其在 Solid Biosciences 的持股增加了 96.1%。Bain Capital Life Sciences Investors LLC 现在持有 7,911,669 股该公司的股票，价值 2927.3 万美元，此前在上个季度又购买了 3,877,087 股。Siren L.L.C.在第一季度将其在 Solid Biosciences 的持股增加了 97.8%。Siren L.L.C.现在持有 7,415,905 股该公司的股票，价值 2743.9 万美元，此前在上个季度又购买了 3,666,864 股。MPM Bioimpact LLC 在第一季度购买了 Solid Biosciences 的新头寸，价值约 607.7 万美元。最后，Redmile Group LLC 在第一季度将其在 Solid Biosciences 的持股增加了 228.2%。Redmile Group LLC 现在持有 2,019,171 股该公司的股票，价值 747.1 万美元，此前在上个季度又购买了 1,403,925 股。机构投资者持有该公司 81.46% 的股份。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票分析师最近对该公司发表了看法。Wedbush 在 8 月 13 日的报告中将 Solid Biosciences 的目标价从 17.00 美元下调至 14.00 美元，并对该股票给予 “跑赢大盘” 的评级。Weiss Ratings 在 10 月 8 日的报告中重申了对 Solid Biosciences 股票的 “卖出（d-）” 评级。Wall Street Zen 在 10 月 11 日的报告中将 Solid Biosciences 的评级从 “卖出” 上调至 “持有”。Chardan Capital 在 8 月 14 日的研究报告中重申了 “买入” 评级，并对 Solid Biosciences 的股票设定了 15.00 美元的目标价。最后，花旗集团在 6 月 26 日的研究报告中开始覆盖 Solid Biosciences。他们对该股票给予 “买入” 评级，并设定了 14.00 美元的目标价。一位投资分析师对该股票给予了强烈买入评级，十位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，共识目标价为 15.00 美元。</p>
<ul>
<li>Sarepta 因致死事件下跌 42%；市场关注 Solid Biosciences</li>
</ul>
<p><strong>获取我们最新的 SLDB 股票报告</strong></p>
<h2>Solid Biosciences 股票下跌 2.5%</h2>
<p>NASDAQ:SLDB 周五开盘价为 6.16 美元。该公司的市值为 4.7968 亿美元，市盈率为-2.20，贝塔值为 2.53。Solid Biosciences Inc.的 12 个月最低价为 2.41 美元，最高价为 7.37 美元。该股票的 50 日移动平均价格为 5.76 美元，200 日移动平均价格为 4.77 美元。</p>
<ul>
<li>Solid Biosciences 能否在 DMD 市场挑战 Sarepta？</li>
</ul>
<p>Solid Biosciences（NASDAQ:SLDB - 获取免费报告）在 8 月 12 日星期二发布了其财报。该公司报告的每股收益为（0.42 美元），超过分析师共识预期的（0.51 美元）0.09 美元。作为一个整体，分析师预计 Solid Biosciences Inc.在本年度的每股收益为-2.84 美元。</p>
<h2>Solid Biosciences 公司简介</h2>
<p>（免费报告）</p>
<p>Solid Biosciences Inc.是一家生命科学公司，开发用于治疗美国神经肌肉和心脏疾病的疗法。该公司的主要产品候选者是 SGT-003，一种用于治疗杜氏肌营养不良症的基因转移候选者；以及 SGT-501 用于治疗儿茶酚胺多形性室性心动过速。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票而非 Solid Biosciences</li>
<li>如何使用 MarketBeat 股票筛选器</li>
<li>Salesforce 期待已久的拐点来了：继续上涨！</li>
<li>什么是 MACD 指标以及如何在交易中使用它</li>
<li>Rocket Lab USA 获得华尔街的认可：是时候买入了吗？</li>
<li>为什么这些公司被认为是蓝筹股？</li>
<li>Archer 以战略性举措收购竞争对手的专利宝藏</li>
</ul>
<p><strong>想看看其他对冲基金持有 SLDB 的情况吗？</strong> 访问 HoldingsChannel.com 获取 Solid Biosciences Inc.（NASDAQ:SLDB - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Solid Biosciences 吗？</h2>
<p>在考虑 Solid Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而 Solid Biosciences 并不在名单上。</p>
<p>虽然 Solid Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

SLDB

<p>根据最近的 SEC 文件，Blair William & Co. IL 在第二季度收购了 165,700 股 Solid Biosciences Inc.（NASDAQ:SLDB），价值约为 807,000 美元。这次购买使他们的持股比例达到约 0.21%。其他机构投资者也增加了对 SLDB 的持股，其中 Adage Capital Partners 和 Bain Capital Life Sciences 的增持尤为显著。分析师对该股票的评级不一，普遍目标价为 15.00 美元。Solid Biosciences 报告每股收益为（0.42 美元），超出预期</p>

<p>Blair William &amp; Co. IL bought a new position in shares of Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm bought 165,700 shares of the company's stock, valued at approximately $807,000. Blair William &amp; Co. IL owned about 0.21% of Solid Biosciences at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据 Blair William &amp; Co. IL 在最近向证券交易委员会提交的 13F 文件，该公司在第二季度购买了 Solid Biosciences Inc.（NASDAQ:SLDB - 免费报告）股票的新头寸。该公司购买了 165,700 股，价值约为 807,000 美元。Blair William &amp; Co. IL 在最近一个季度末持有 Solid Biosciences 约 0.21% 的股份。</p>
</div><p>Get <strong>Solid Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Solid Biosciences</strong> 警报：</p>
</div><ul>
<li>Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta 在 2025 年遭遇重创——分析师仍然预测 179% 的上涨空间</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SLDB. Adage Capital Partners GP L.L.C. boosted its holdings in Solid Biosciences by 285.0% during the first quarter. Adage Capital Partners GP L.L.C. now owns 6,729,484 shares of the company's stock worth $24,899,000 after buying an additional 4,981,400 shares during the last quarter. Bain Capital Life Sciences Investors LLC boosted its holdings in Solid Biosciences by 96.1% during the first quarter. Bain Capital Life Sciences Investors LLC now owns 7,911,669 shares of the company's stock worth $29,273,000 after buying an additional 3,877,087 shares during the last quarter. Siren L.L.C. boosted its holdings in Solid Biosciences by 97.8% during the first quarter. Siren L.L.C. now owns 7,415,905 shares of the company's stock worth $27,439,000 after buying an additional 3,666,864 shares during the last quarter. MPM Bioimpact LLC bought a new position in Solid Biosciences during the first quarter worth about $6,077,000. Finally, Redmile Group LLC boosted its holdings in Solid Biosciences by 228.2% during the first quarter. Redmile Group LLC now owns 2,019,171 shares of the company's stock worth $7,471,000 after buying an additional 1,403,925 shares during the last quarter. Institutional investors own 81.46% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也增加或减少了在 SLDB 的持股。Adage Capital Partners GP L.L.C.在第一季度将其在 Solid Biosciences 的持股增加了 285.0%。Adage Capital Partners GP L.L.C.现在持有 6,729,484 股该公司的股票，价值 2498.9 万美元，此前在上个季度又购买了 4,981,400 股。Bain Capital Life Sciences Investors LLC 在第一季度将其在 Solid Biosciences 的持股增加了 96.1%。Bain Capital Life Sciences Investors LLC 现在持有 7,911,669 股该公司的股票，价值 2927.3 万美元，此前在上个季度又购买了 3,877,087 股。Siren L.L.C.在第一季度将其在 Solid Biosciences 的持股增加了 97.8%。Siren L.L.C.现在持有 7,415,905 股该公司的股票，价值 2743.9 万美元，此前在上个季度又购买了 3,666,864 股。MPM Bioimpact LLC 在第一季度购买了 Solid Biosciences 的新头寸，价值约 607.7 万美元。最后，Redmile Group LLC 在第一季度将其在 Solid Biosciences 的持股增加了 228.2%。Redmile Group LLC 现在持有 2,019,171 股该公司的股票，价值 747.1 万美元，此前在上个季度又购买了 1,403,925 股。机构投资者持有该公司 81.46% 的股份。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities analysts have recently weighed in on the company. Wedbush cut their price objective on Solid Biosciences from $17.00 to $14.00 and set an &#34;outperform&#34; rating on the stock in a report on Wednesday, August 13th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Solid Biosciences in a report on Wednesday, October 8th. Wall Street Zen upgraded Solid Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, October 11th. Chardan Capital reissued a &#34;buy&#34; rating and issued a $15.00 target price on shares of Solid Biosciences in a research report on Thursday, August 14th. Finally, Citigroup began coverage on Solid Biosciences in a research report on Thursday, June 26th. They issued a &#34;buy&#34; rating and a $14.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $15.00.</p>
<div class="lb-trans"><p>几位股票分析师最近对该公司发表了看法。Wedbush 在 8 月 13 日的报告中将 Solid Biosciences 的目标价从 17.00 美元下调至 14.00 美元，并对该股票给予 “跑赢大盘” 的评级。Weiss Ratings 在 10 月 8 日的报告中重申了对 Solid Biosciences 股票的 “卖出（d-）” 评级。Wall Street Zen 在 10 月 11 日的报告中将 Solid Biosciences 的评级从 “卖出” 上调至 “持有”。Chardan Capital 在 8 月 14 日的研究报告中重申了 “买入” 评级，并对 Solid Biosciences 的股票设定了 15.00 美元的目标价。最后，花旗集团在 6 月 26 日的研究报告中开始覆盖 Solid Biosciences。他们对该股票给予 “买入” 评级，并设定了 14.00 美元的目标价。一位投资分析师对该股票给予了强烈买入评级，十位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，共识目标价为 15.00 美元。</p>
</div><ul>
<li>Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta 因致死事件下跌 42%；市场关注 Solid Biosciences</li>
</ul>
</div><p><strong>Get Our Latest Stock Report on SLDB</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 SLDB 股票报告</strong></p>
</div><h2>Solid Biosciences Stock Down 2.5%</h2>
<div class="lb-trans"><h2>Solid Biosciences 股票下跌 2.5%</h2>
</div><p>NASDAQ:SLDB opened at $6.16 on Friday. The firm has a market capitalization of $479.68 million, a price-to-earnings ratio of -2.20 and a beta of 2.53. Solid Biosciences Inc. has a twelve month low of $2.41 and a twelve month high of $7.37. The stock's 50 day moving average price is $5.76 and its two-hundred day moving average price is $4.77.</p>
<div class="lb-trans"><p>NASDAQ:SLDB 周五开盘价为 6.16 美元。该公司的市值为 4.7968 亿美元，市盈率为-2.20，贝塔值为 2.53。Solid Biosciences Inc.的 12 个月最低价为 2.41 美元，最高价为 7.37 美元。该股票的 50 日移动平均价格为 5.76 美元，200 日移动平均价格为 4.77 美元。</p>
</div><ul>
<li>Can Solid Biosciences Challenge Sarepta in the DMD Market?</li>
</ul>
<div class="lb-trans"><ul>
<li>Solid Biosciences 能否在 DMD 市场挑战 Sarepta？</li>
</ul>
</div><p>Solid Biosciences (NASDAQ:SLDB - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.42) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09. As a group, analysts anticipate that Solid Biosciences Inc. will post -2.84 earnings per share for the current year.</p>
<div class="lb-trans"><p>Solid Biosciences（NASDAQ:SLDB - 获取免费报告）在 8 月 12 日星期二发布了其财报。该公司报告的每股收益为（0.42 美元），超过分析师共识预期的（0.51 美元）0.09 美元。作为一个整体，分析师预计 Solid Biosciences Inc.在本年度的每股收益为-2.84 美元。</p>
</div><h2>Solid Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Solid Biosciences 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.</p>
<div class="lb-trans"><p>Solid Biosciences Inc.是一家生命科学公司，开发用于治疗美国神经肌肉和心脏疾病的疗法。该公司的主要产品候选者是 SGT-003，一种用于治疗杜氏肌营养不良症的基因转移候选者；以及 SGT-501 用于治疗儿茶酚胺多形性室性心动过速。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Solid Biosciences</li>
<li>How to Use the MarketBeat Stock Screener</li>
<li>Salesforce’s Long-Awaited Inflection is Here: Rally On!</li>
<li>What is the MACD Indicator and How to Use it in Your Trading</li>
<li>Rocket Lab USA Receives Wall Street Validation: Time to Buy?</li>
<li>Why Are These Companies Considered Blue Chips?</li>
<li>Archer Buys Rival's Patent Treasure Trove in Strategic Move</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非 Solid Biosciences</li>
<li>如何使用 MarketBeat 股票筛选器</li>
<li>Salesforce 期待已久的拐点来了：继续上涨！</li>
<li>什么是 MACD 指标以及如何在交易中使用它</li>
<li>Rocket Lab USA 获得华尔街的认可：是时候买入了吗？</li>
<li>为什么这些公司被认为是蓝筹股？</li>
<li>Archer 以战略性举措收购竞争对手的专利宝藏</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding SLDB?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solid Biosciences Inc. (NASDAQ:SLDB - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有 SLDB 的情况吗？</strong> 访问 HoldingsChannel.com 获取 Solid Biosciences Inc.（NASDAQ:SLDB - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=SLDB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Solid Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Solid Biosciences 吗？</h2>
</div><p>Before you consider Solid Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Solid Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而 Solid Biosciences 并不在名单上。</p>
</div><p>While Solid Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Solid Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Blair William & Co. IL 购入了 165,700 股 Solid Biosciences Inc. $SLDB 的股票